Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Glucose Intolerance

Glucose Intolerance

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Glucose Intolerance

13 trials tracked for Glucose Intolerance: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 38 citations.

13Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 3 Phase 1 1 Other / NA 6
  1. Phase 3 A Trial of Tadalafil and Glycemic Traits Completed · 38 cited
  2. Phase 4 Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Completed
  3. Phase 4 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Completed
  4. Phase 2 Healthy Aging Through Functional Food Completed
  5. Phase 2 Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105) Completed
  6. Phase 2 Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes Completed
Show 7 more trials
  1. Phase 1 Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids Completed
  2. N/A Influence of Nocturnal Light Exposure on the Impairment of Glucose Tolerance Induced by Chronic Sleep Restriction Completed
  3. N/A Multicomponent Telecare Model for Supporting Prediabetes Patients Completed
  4. N/A Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial Completed
  5. N/A Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion Completed
  6. N/A In Vitro Fertilization Impact on Metabolic Parameters Completed
  7. N/A Comparison of Two Screening Strategies for Gestational Diabetes (GDM2) Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Glucose Intolerance: what the trials found

Clinical evidence regarding the management of glucose intolerance includes investigations into various pharmacological agents. Cyanocobalamin has been evaluated in a Phase 4 trial 1.

Dexmedetomidine was studied in a Phase 4 trial for its effects on metabolic markers; while it showed significant changes in plasmantic insulin levels (p=0.02), there were no statistically significant changes in plasmantic glucose levels (p=0.38) 2. Tadalafil was evaluated in a Phase 3 trial, but did not produce statistically significant changes in insulin resistance (p=0.34), insulin sensitivity (p=0.18), or endothelial function (p=0.76) 3.

Recent results — preliminary, needs further review

  • Sleep restriction with ALAN followed by sleep restriction without ALAN was evaluated in a recent study 8.

For the clinician treating this condition

  • Dexmedetomidine is associated with significant changes in plasmantic insulin levels, though it did not significantly impact plasmatic glucose levels.
  • Tadalafil did not demonstrate statistically significant improvements in HOMA-IR, Matsuda Index, or endothelial function over a 3-month period.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.